Valuation: Viyash Scientific Limited

Market Cap 121B 1.27B 1.1B 1.03B 942M 1.77B 1.8B 12.04B 4.72B 60.59B 4.77B 4.67B 200B P/E 2027 *
33.2x
P/E 2028 * 20.8x
Enterprise Value 121B 1.27B 1.1B 1.03B 942M 1.77B 1.8B 12.04B 4.72B 60.59B 4.77B 4.67B 200B EV / Sales 2027 *
3.1x
EV / Sales 2028 * 2.73x
Free-Float
32.55%
Yield 2027 *
-
Yield 2028 * -
1 day+1.54%
1 week+10.00%
Current month+9.94%
1 month-4.25%
3 months+26.16%
6 months+37.45%
Current year+33.13%
1 week 252.5
Extreme 252.5
281.15
1 month 248.05
Extreme 248.05
286
Current year 178.4
Extreme 178.4
297.9
1 year 167.45
Extreme 167.45
297.9
3 years 86.03
Extreme 86.03
297.9
5 years 61.8
Extreme 61.8
297.9
10 years 42.45
Extreme 42.45
336.4
Manager TitleAgeSince
Chief Executive Officer 62 15/12/2025
Director of Finance/CFO - 31/12/2025
Chief Tech/Sci/R&D Officer - 04/02/2026
Director TitleAgeSince
Chairman 78 -
Director/Board Member 66 24/08/2020
Director/Board Member 57 10/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
+1.54%+10.00%+55.94%+199.11% 1.25B
-0.52%+2.66%+58.86%+163.79% 1,062B
+0.88%+1.34%+51.97%+53.36% 619B
+0.89%-4.42%+25.34%+66.55% 431B
+0.71%+3.93%+47.75%+38.58% 358B
+0.64%-0.63%+36.39%+41.44% 293B
+0.39%-6.48%+7.62%+9.04% 247B
+1.51%+6.01%+44.36%+68.92% 219B
+3.92%-7.80%+5.39%-42.52% 200B
+1.80%+1.47%+20.79%+69.31% 162B
Average +1.15%-0.88%+35.44%+66.76% 359.35B
Weighted average by Cap. +0.66%-0.82%+41.61%+78.47%

Financials

2027 *2028 *
Net sales 38.99B 410M 354M 331M 304M 571M 580M 3.88B 1.52B 19.54B 1.54B 1.5B 64.64B 44.28B 465M 402M 376M 345M 648M 658M 4.41B 1.73B 22.18B 1.75B 1.71B 73.41B
Net income 3.83B 40.25M 34.82M 32.51M 29.84M 56.12M 56.96M 381M 150M 1.92B 151M 148M 6.35B 5.82B 61.16M 52.9M 49.4M 45.34M 85.26M 86.54M 580M 227M 2.92B 230M 225M 9.65B
Net Debt - -
Logo Viyash Scientific Limited
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical services. The Company has eight manufacturing facilities, based in India, Turkey, Brazil, Spain and Germany. It is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It specializes in analytical and bioanalytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It offers analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer-developed methods or in-house method development.
Employees
2,900
Date Price Change Volume
07/08/26 ₹277.10 +1.54% 96,153
06/08/26 ₹272.90 -0.24% 58,342
05/08/26 ₹273.55 +2.66% 150,611
04/08/26 ₹266.45 +0.99% 102,577
03/08/26 ₹263.85 +4.68% 149,920
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
277.10INR
Average target price
312.67INR
Spread / Average Target
+12.84%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VIYASH Stock